You just read:

Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion Meets Primary Endpoint

News provided by

AbbVie

12 Aug, 2015, 13:30 BST